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Effects of kisspeptin on diabetic rat platelets1
Zsóﬁa Mezei, Sándor Váczi, Viktória Török, Csaba Stumpf, Rita Ónody, Imre Földesi, and Gyula Szabó
Abstract: Hyperglycemia, hyperlipidemia, and free radicals result in platelet activation and atherogenesis. Kisspeptin (KP) is
able to regulatemetabolism, hemostasis, and the development of atherosclerosis. We examined whether platelet aggregation of
streptozotocin-induced diabetic rats depends on the inducer type and if KP-13 and RF-9 (a kisspeptin receptor modiﬁer) can
inﬂuence platelet function. We measured the speed and the maximum of aggregation, along with the area under the curve.
Serum glucose and calcium levels and urine formation of diabetic animals increased, while the body mass and platelet count
decreased. Collagen was the most effective inducer of platelet aggregation. The aggregability of nondiabetic platelets was
elevated in the presence of 5 × 10−8 mol/L KP-13. This effect was less expressed in diabetic animals. The effectivity of RF-9 was
stronger than that of KP-13 in nondiabetic platelets, however it was ineffective in diabetic animals. RF-9 pre-treatment did not
change the effects of 5 × 10−8 mol/L KP-13 in either animal group. The in vivo activation of diabetic platelets, which may be due
to elevated serum calcium, induces thrombocytopenia andmay lead to reduced in vitro aggregability.We could not demonstrate
the antagonistic effect of RF-9 against KP-13 in isolated platelets.
Key words: kisspeptin, platelets, aggregation, RF-9, diabetes, streptozotocin, aggregometry.
Résumé : L’hyperglycémie, l’hyperlipidémie et les radicaux libres mènent a` l’activation des plaquettes et a` l’athérogénèse. Par
ailleurs, la kisspeptine (KP) est en mesure de réguler le métabolisme, l’homéostasie et la formation de l’athérosclérose. Nous
avons cherché a` observer chez des rats atteints d’un diabète induit par la streptozotocine si l’agrégation plaquettaire dépend du
type d’inducteur et si le KP-13 et le RF-9 (un modiﬁcateur des récepteurs de la kisspeptine) peuvent inﬂuencer la fonction
plaquettaire. Nous avons mesuré la vitesse et le maximum de l’agrégation, ainsi que l’aire sous la courbe. Chez les animaux
atteints de diabète, les taux sériques de glucose et de calcium, ainsi que la formation d’urine ont augmenté, alors que la masse
corporelle et le nombre de plaquettes ont diminué. Le collagène constituait l’inducteur de l’agrégation plaquettaire le plus
efﬁcace. Sous KP-13 a` 5 × 10–8 mol/L, l’agrégabilité des plaquettes augmentait en absence de diabète. Cet effet était moinsmarqué
chez les animaux atteints de diabète. Inefﬁcace sur les plaquettes d’animaux atteints de diabète, le RF-9 était plus efﬁcace que le
KP-13 en absence de diabète. L’administration préalable de RF-9 n’entraînait des variations des effets du KP-13 a` 5 × 10–8 mol/L
dans aucun des groupes. En présence de diabète, l’activation des plaquettes in vivo, qui pourrait être causée par l’augmentation
des taux sériques de calcium, provoque une thrombocytopénie, et pourrait mener a` une diminution de l’agrégabilité in vitro.
Nous n’avons pas été en mesure de montrer l’effet antagoniste du RF-9 contre le KP-13 dans des plaquettes isolées. [Traduit par
la Rédaction]
Mots-clés : kisspeptine, plaquettes, agrégation, RF-9, diabète, streptozotocine, agrégométrie.
Introduction
Kisspeptins (KPs) are members of the arginine-phenylalanine-
amide (RF-amide) peptide family. The biologically active forms (KP-
54, KP-14, KP-13, KP-10), produced by matrix metalloproteinase
(Pinilla et al. 2012; Tena-Sempere 2013) can bind to their own
receptors (Kirby et al. 2010). One of these is the G protein-coupled
receptor (GPR) 54 receptor that by activating the Gq/11, the extra-
cellular signal-regulated protein kinase 1 and 2 (ERK1/2), and the
p38 mitogen-activated protein (MAP) kinase signaling pathways
(Castaño et al. 2009) might play a role in several intracellular
processes. This receptor is antagonized by KP-234 (Roseweir et al.
2009). Another receptor type is the neuropeptide FF (NPFF) recep-
tors (Elhabazi et al. 2013; Lyubimov et al. 2010) that can be coupled
to Gi/o proteins leading to the inhibition of adenylate cyclase,
resulting in the reduction of cytoplasmic cyclic adenosine mono-
phosphate concentration (Mollereau et al. 2002). RF-9 (1-adamantane
carbonyl-Arg-Phe-NH2) is a synthetic peptide that might have a
potentially antagonistic effect on KP-13 (Simonin et al. 2006).
KPs can participate in the regulation of the reproductive axis
(Colledge 2009), the cardiovascular system (Maguire et al. 2011;
Mead et al. 2007; Mezei et al. 2015; Sawyer et al. 2011), hemostasis
(Qureshi and Kanwal 2011), food intake (Dudek et al. 2016; Hussain
et al. 2015; Rao et al. 2013; Tolson et al. 2014; Wahab et al. 2013),
and various metabolic pathways (Silvestre et al. 2008; Song et al.
2014).
Kisspeptins (KP-54, KP-13) in a nanomolar concentration can
inhibit insulin secretion but only at the physiological concentra-
tion of glucose (Vikman and Ahrén 2009). Glucagon may mediate
this process, because by stimulating the kisspeptin production of
the liver it can suppress the glucose-induced insulin secretion
(Song et al. 2014). It is known that impaired KP production inhibits
the metabolism and glucose intolerance (Tolson et al. 2014); and
obesity (Hussain et al. 2015; Tolson et al. 2014) may develop. Ac-
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cording to Dudek et al. (2016) in the case of diabetic Type 1 rats,
very low (e.g., liver and fat) or completely absent KP/GPR54 signal-
ing (e.g., pancreas) may contribute to the impaired regulation of
glucose-induced insulin secretion.
Diabetes mellitus is characterized by abnormal carbohydrate,
lipid, and protein metabolism. These pathophysiological pro-
cesses result in hyperglycemia, dyslipidemia, overproduction of
reactive oxygen species (ROS), and inﬂammatorymediators. These
changes can induce endothelial dysfunction, atherosclerosis,
platelet activation, and pro-thrombotic condition (Hess et al. 2012;
Rofﬁ et al. 2011; Randriamboavonjy et al. 2012).
Thepresenceof theKP systemwasdetected also in atherosclerosis-
prone vessels (Mead et al. 2007) and in the developed edema
(Sawyer et al. 2011). The latter was antagonized by cyclooxygenase
inhibition. A recent publication reported that KP has an antico-
agulant activity that might be mediated through changes in Ca
signaling, consequently leading to a decreased thrombin concen-
tration and platelet number reduction (Qureshi and Kanwal 2011).
Platelets may serve as an important link between inﬂammation,
thrombosis, and atherogenesis (Hadi and Suwaidi 2007).
In our earlier experiments, we detected an elevated eicosanoid
synthesis of rat platelets in the presence of KP-13 (Mezei et al.
2015).
Therefore in the present study, we aimed to investigate the
effect of KP-13 (a biologically active form of KP that binds to both
GPR54 and NPFF receptors) and its presumed antagonist, RF-9
peptide, on the platelet aggregation of streptozotocin-induced di-
abetic rats.
Methods
Chemicals
Hirudin blood tubes, disposablemultiplate test cells, and induc-
ers of platelet aggregation (ADPItest, ASPItest [arachidonic acid]
and COLtest) were purchased from Roche Ltd. (Budapest, Hun-
gary). KP-13 and RF-9 were purchased from Bachem (Bubendorf,
Switzerland). Streptozotocin was obtained from Amresco (Solon,
Ohio, USA). The original reagents for the determination of hema-
tological parameters were purchased from Sysmex Ltd. (Budapest,
Hungary). High-density lipoprotein (HDL) and triglyceride tests
were purchased from DiaSys Diagnostic Systems GmbH (Hol-
zheim, Germany), while the other tests for determining the chem-
ical parameters originate from Roche Ltd. (Budapest, Hungary).
Animals
Animal experiments were performed under a protocol accepted
by the Ethical Committee for the Protection of Animals in Re-
search at the University of Szeged, Hungary. All experiments were
carried out in accordance with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health.
Streptozotocin (STZ) was used to induce diabetes in Wistar-
Kyoto male rats (weighing 210–230 g, n = 6 animals). Sixty-ﬁve milli-
grams of STZ was dissolved in 2 mL of 10% (w/v) sucrose prepared
just before the use. The intraperitoneal injection of STZ (65mg/kg)
was repeated 3 days later, using the same dose. Nondiabetic rats
(weighing 210–230 g, n = 6 animals) were injected with the solvent
as vehicle. After STZ injection, the drinking water of animals was
changed for 10% (w/v) sucrose solution for 24 h (Furman 2015). The
animals were maintained on 12 h dark/12 h light cycles in a room
at constant temperature (23 ± 1 °C) with free access to standard
laboratory food and water ad libitum.
Wemonitored serum glucose levels, food and ﬂuid intake,mass
and urine volume of the animals during the development of dia-
betes. Determination of urine volume was carried out by round-
the-clock urine collection using a metabolic cage on Day 14 after
the second STZ administration. Four weeks later the animals were
anesthetized by Euthasol (i.p. 30 mg/kg).
Determining the laboratory parameters of rats
The hematological parameters were determined by Sysmex
XE 2100 Automated Hematology System (Sysmex Ltd., Budapest,
Hungary). This system utilizes ﬂuorescent ﬂow cytometry and hy-
drodynamic focusing technologies. White blood cell (leukocyte)
differential count and optical platelet count were determined by
ﬂuorescent ﬂow cytometry. The platelet (thrombocyte), red blood
cell (RBC), hematocrit (HCT) were detected by DC sheath ﬂow.
Hemoglobin was detected using Sysmex SULFOLYSER. These mea-
surements were carried out using the original reagents of Sysmex.
The chemical parameters of blood were determined by Hitachi
Modular analyzers (Roche Ltd., Budapest, Hungary). The liver
function was examined by detecting aspartate aminotransferase
(ASAT) and alanine aminotransferase (ALAT) using a UV test and
ALP by colorimetric assay in the serum. Kidney function was ana-
lyzed by measuring serum creatinine (kinetic colorimetric assay)
and serum urea by kinetic UV assay. The serum glucose levels
were measured by enzymatic colorimetric assay. The serum lipid
parameters were determined as serum HDL cholesterol (time-
consuming precipitation method) and serum triglycerides (color-
imetric enzymatic test). Serum low-density lipoprotein (LDL)
cholesterol was calculated using the Friedewald formula as fol-
lows (all measurements are in mmol/L): LDL cholesterol = Total
cholesterol – HDL cholesterol – (Total triglyceride ÷ 2.19). HDL and
triglyceride tests were purchased from DiaSys Diagnostic Systems
GmbH (Holzheim, Germany), while the other tests originate from
Roche Ltd. (Budapest, Hungary). Results of these assays were com-
pared to the age- and gender-dependent normal values of rat lab-
oratory parameters, published by Charles River Laboratories2.
Multiple electrode aggregometry (MEA)
The Multiplate test principle is based on Cardinal and Flower’s
impedance aggregometry method (introduced in 1980). Unlike in
systems applied earlier, the Multiplate analyzer provides a dispos-
able test cuvette featuring a duplicate sensor. The principle of
MEA is that the electric impedance occurring between the silver-
coated platinum electrodes merging into the blood sample posi-
tively correlates with the rate of platelet aggregation. The SI unit
of impedance is Ohm (). The device, however, uses “arbitrary
units (AU)” (1 AU is equal to approximately 8). The patented twin
sensor technology enables optimal results and an internal quality
control, since 2 parallel measurements are carried out at the same
time. Testing whole blood eliminates the need for time-consuming
sample preparation, while the natural physiological milieu for
platelet function iswell-maintained.Onlya small quantity (300L) of
whole blood is required per test. The aggregometer is capable of
performing 5 measurements simultaneously.
The interpretation of the aggregation curve
The aggregation curve is the quantitative display of the reac-
tion, and it represents the rate of aggregation (AU) plotted against
time. The curve is characterized by the following parameters: area
under the curve (AUC) in units (U) providing the most precise
assessment of the whole reaction; speed in units (AU/min) repre-
senting the slope of the curve (speed of aggregation, SA), which
gives information about the initial kinetics of the reaction (primary
aggregation); peak of the curve in units (AU) showing the maximal
aggregation (MA) during the whole reaction.
2http://www.criver.com/ﬁles/pdfs/rms/cd/rm_rm_r_clinical_parameters_cd_rat_06.aspx.
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The inducers of the reaction
The manufacturer of the aggregometer provides an array of
inducers that provoked platelet aggregation. Using the different
inducers, the pathways of platelet activation can be examined
separately, providing a useful tool in diagnostics regarding platelet
disorders and drug effects. In our current study, we used 3 inducers:
arachidonic acid, ADP, and collagen. The inducers are marketed
in a lyophilized form. Before usage, 1 mL of ion-free water had to
be added carefully, avoiding foam generation. After 10 min stand-
ing at room temperature, the solution was ready to use.
Performing a measurement
Preparation of blood samples
Whole blood was collected from the abdominal aorta of anes-
thetized (Euthasol 30 mg/kg body mass i.p.) rats with a thick nee-
dle and drawn into a plastic tube, containing 15 g/mL hirudin
(Tóth et al. 2006). The specimens were gently mixed by hand with
end-over-end inversion for 3 to 6 times and transported to the
laboratory at room temperature. The aggregometric examination
was carried out within 1.5 h after the collection of blood (Sweeney
et al. 1989).
The platelet count of specimens was determined and standard-
ized. All of the aggregometric cuvettes contained the same num-
ber of platelets (250–350 × 109 platelets/L). When the platelet
count of the sample was higher, it was diluted by its own platelet-
poor plasma. If the sample contained fewer platelets, we applied a
greater amount of blood and a lesser amount of 0.9% NaCl solu-
tion in the aggregometric cuvette. The platelet count was also
measured after the aggregation to detect potential thrombocy-
tolysis.
The total volume of a test cuvette is 620 L. According to the
original measurement protocol of the device, the solution con-
tains the following: 300 L whole blood, 300 L 0.9% sodium
chloride (NaCl) solution, and 20 L inducer. The investigated pep-
tides are not included in this protocol, hencewe had tomodify the
composition of the solution. We used the aggregometer in a semi-
automaticmode. The basic principlewas the following: with every
addition of 20 L peptide (diluted in physiological saline solution)
we reduced the amount of 0.9% NaCl solution with 20 L, thus
keeping the ﬁnal volume of the solution constant (620 L). The
inducers in the 620L solutionwere the following: ADP (6.5mmol/L)
arachidonic acid (0.5 mmol/L) and collagen (3.2 mg/mL).
Examining the effect of inducers on rat platelets
At ﬁrst we assessed the control effect of inducers. 300 L whole
blood and 300 L 0.9% NaCl solution were added into the test
cuvette. After 3 min of incubation outside the aggregometer, the
cuvette was attached to the device and another 3 min of incuba-
tion was performed. Then the aggregation reaction was initiated
by administering 20 L of inducer (ADP, arachidonic acid, or col-
lagen). The measurement was performed with all 3 inducers in
each animal.
Examining the effect of peptides on rat platelets
KP-13 (the presumed agonist) and RF-9 (the presumed antago-
nists) were investigated. The following peptide concentrations
were applied: 0, 1.25 × 10−8, 2.5 × 10−8, 5 × 10−8, 10 × 10−8 mol/L.
We examined the sole effect of each peptide. In these experi-
mental arrangements 20 L peptide was added to 300 L blood
and 280 L saline. After 3 min of incubation outside the ag-
gregometer, the cuvette was attached to the device and another
3 min of incubation was performed. Then the aggregation reac-
tion was initiated by administering 20 L of inducer (ADP, arachi-
donic acid, or collagen). Themeasurement was performedwith all
3 inducers for every animal’s blood samples.
To verify the antagonistic activity of RF-9, the sample had to be
pre-incubated with one of the aforementioned peptides before
the addition of KP-13. TwentyL of RF-9 was added to 300L blood
diluted with 260 L saline. After 3 min of incubation the test cell
was attached to the aggregometer and KP-13 was added. The reac-
tion was initiated after another 3 min of incubation by adminis-
tering 20 L of inducer (ADP, arachidonic acid, or collagen). The
measurement was performed with all 3 inducers on every ani-
mal’s blood samples.
Statistical analysis
The results are expressed as means ± SE. The signiﬁcance of the
differences between the platelet aggregation of the peptide-
treated and untreated platelets in diabetic or nondiabetic rats was
determined by one-way analysis of variance (ANOVA), followed by
Tukey’s multiple comparison post hoc test. This statistical analy-
sis was also carried out at the same peptide concentration be-
tween the diabetic and nondiabetic groups. A difference at a level
p < 0.05 was considered statistically signiﬁcant. The statistical
analysis was performed by SPSS version 22.0 (IBM Corp. Released
2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY:
IBM Corp.).
Results
The development of STZ-induced diabetes in male rats was con-
ﬁrmed by a signiﬁcant elevation in water drinking (from 263.8 ±
10.1 mL/week to 938 ± 49.9 mL/week) and in food intake (from
202.2 ± 3.2 to 224 ± 5.2 g/week) (Table 1). Parallel with this, we
detected a 40.2% reduction in body weight and 43.4% elevation in
urine formation in diabetic animals compared to the nondiabetic
control rats (Table 1).
The development of diabetes mellitus was also veriﬁed by the
signiﬁcant increase in serumglucose level, from9.5 ± 0.45mmol/L
to 25.4 ± 0.88mmol/L (Table 2). This serum glucose level was about
2.5 times higher than the highest normal parameter published by
Charles River Laboratories. Serum calcium (3.2 ± 0.08 vs. 2.8 ±
0.02mmol/L), ALAT (83.6 ± 8.58 vs. 38.7 ± 2.17 U/L), ALP (265 ± 23.54
vs. 77.7 ± 4.03 U/L) and urea (11.2 ± 0.95 vs. 6.9 ± 0.27mmol/L) levels
of diabetic rats were also signiﬁcantly elevated, compared to
those of nondiabetic animals. These parameters were higher than
the normal values published by Charles River Laboratories, while
the serum triglyceride was elevated (1.5 ± 0.27 vs. 0.9 ± 0.1 mmol/L)
only when we compared it to the values of nondiabetic rats
(Table 2).
Both the RBC (7.4 ± 0.2 vs. 8.1 ± 0.11 × 1012/L) and the platelet
count (292.8 ± 22.53 vs. 367.3 ± 10.92 x 109/L) were signiﬁcantly
lower in the diabetic rats, compared to the nondiabetic animals,
and these numbers are lower than the normal physiological val-
ues (Table 3). Parallel with this, we detected lower hemoglobin
(129.4 ± 2.8 vs. 141.2 ± 2.24 g/L) and mean corpuscular hemoglobin
concentration (346.8 ± 3.81 vs. 369.3 ± 2.33 g/L) concentrations in
the diabetic group. Hematocrit was not different from the control
animals, while the plateletcrit (the mass of platelets) was reduced
in the diabetic rats (0.2 ± 0.02 vs. 0.3 ± 0.01%), compared to the
nondiabetic animals (Table 3).
We compared the aggregatory effects of different inducers (ADP,
arachidonic acid, collagen) in nondiabetic (Table 4A) and diabetic
Table 1. Physical parameters of diabetic and nondiabetic
rats.
Nondiabetic
rats Diabetic rats
Mean water intake (mL/week) 263.8 (10.1) 938.0* (49.9)
Mean food intake (g/week) 202.2 (3.2) 224.0* (5.2)
Final body mass (g) 475.0 (6.2) 283.6* (20.5)
Mean urine volume (mL/day) 122.2 (3.4) 175.4* (5.9)
Note: Data are mean ± (SE) of 6 samples/animals. Body mass was
measured before anesthesia. Urine volume was measured on Day 14
after the second STZ administration and was expressed in mL/day.
STZ, streptozotocin. *p < 0.05 diabetic vs. nondiabetic rats.
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(Table 4B) rat platelets. We measured 3 characteristic parameters
of the aggregation curves (AUC, MA, SA). All these parameters
were found to be the highest in case of collagen-induced platelet
aggregation in both animal groups (Table 4).
Therefore we examined the effect of KP-13 and RF-9 on the
collagen-induced aggregation of nondiabetic and diabetic rat
platelets. KP-13 (5 × 10−8 mol/L) induced signiﬁcant increase in
nondiabetic rat platelet aggregation compared to the peptide-free
controls. This effect is represented by an increase in AUC (from
56.9 ± 3.26 to 69.73 ± 3.27 U), an elevation in MA (from 78.33 ± 4.2
to 97.39 ± 4.19 AU), and in SA (from 23.49 ± 1.67 to 28.21 ± 1.68 AU/
min) (Fig. 1A). Although we increased the peptide concentration
further, no augmentation of platelet aggregation was observed
(i.e., we obtained a plateau-shaped dose–response curve). Since in
the presence of KP-13 we detected signiﬁcant elevation (by 22%)
only in case of MA, an increased platelet aggregability of diabetic
rats could not be sufﬁciently demonstrated in vitro (Fig. 1B). The
speed of the collagen-induced aggregation of nondiabetic plate-
lets was signiﬁcantly increased by 5 × 10−8 KP-13 (28.21 ± 1.68 AU/
min, Fig. 1A) compared to diabetic rats (22.8 ± 1.76 AU/min, Fig. 1B).
When we tested RF-9, a presumed KP antagonist, we detected
signiﬁcant augmentation of platelet aggregation in nondiabetic
rats (Fig. 2A) already at a concentration of 2.5 × 10−8 mol/L com-
pared to the peptide-free control, while the same concentration of
KP-13 (Fig. 1A) did not induce signiﬁcant elevation. At this concen-
tration, RF-9 increased the AUC, MA, and SA (by 29%, 28.9%, and
28.6%, respectively) compared to the peptide-untreated samples of
nondiabetic rats (Fig. 2A), while the same concentration of KP-13
induced only a moderate elevation in these parameters (AUC and
MA by 16.6%, SA by 14.5%, Fig. 1A). The dose–response curve of RF-9
was the same as the one induced by KP-13. The aggregation of
diabetic platelets was notmodiﬁed signiﬁcantly by any of the RF-9
concentrations applied (Fig. 2B). On the other hand, the AUC
(75.6 ± 4.8 vs. 58.8 ± 4.9 U) and the MA (107.72 ± 6.23 vs. 86.78 ±
6.22 AU) signiﬁcantly increased in nondiabetic platelets (Fig. 2A),
compared to diabetic thrombocytes (Fig. 2B) in the presence of
10 × 10−8 mol/L RF-9.
The platelet aggregation increasing effect of 5 × 10−8mol/L KP-13
was not prevented by the pre-treatment with various concentra-
tions of RF-9 (Fig. 3). The aggregability of nondiabetic platelets was
signiﬁcantly higher than that of diabetic animals already at 2.5 ×
10−8 mol/L concentration of RF-9 as a pre-treatment and at 5 ×
10−8mol/L concentration of KP-13 as treatment (AUC 70.4 ± 4.84 vs.
51 ± 5.4 U, MA 99 ± 6.2 vs 77.18 ± 6.96 AU, SA 27 ± 2.49 vs. 19.55 ±
2.78 AU/min). This signiﬁcant difference between the 2 animal
groups can be explained by the fact that the platelet aggregation
of nondiabetic animals was signiﬁcantly elevated (Fig. 3A), while
that of diabetic rats was moderately reduced (Fig. 3B).
Discussion
It is well known that the molecular structure of streptozotocin
contains glucose and N-methyl-N-nitrosourea groups, both play-
ing a role in the induction of diabetes mellitus in different ani-
mals (e.g., in rats) (Elsner et al. 2000). The glucose binding to the
glucose transporter-2 (GLUT-2) receptor of pancreatic  cells helps
the intake of STZ by these cells. The N-methyl-N-nitrosourea group
induces DNA methylation (Szkudelski 2012), alkylation (Friederich
et al. 2009) and oxidation (Gul et al. 2002) leading to the apoptosis
of pancreatic  cells. Many physical parameters (polyuria, polydip-
sia, polyphagia, and losing of body mass) and laboratory data
(elevation of glucose level, dyslipidemia), which were detected in
our experiments, verify the generation of diabetes in rats by strep-
tozotocin. The GLUT-2 transporter can be found not only on the
pancreatic  cells but also on the hepatocytes and renal tubular
epithelial cells (Eleazu et al. 2013; Valentovic et al. 2006). There-
fore, the detected abnormal functions of the liver (elevated ALAT,
ALP, triglyceride) and kidney (urine, creatinine) are assumed to be
Table 2. Chemical laboratory parameters of serum in
diabetic and nondiabetic rats.
Nondiabetic
rats Diabetic rats
Glucose (mmol/L) 9.5 (0.45) 25.4* (0.88)
CHOL (mmol/L) 2.1 (0.23) 2.5 (0.24)
TG (mmol/L) 0.9 (0.10) 1.5* (0.27)
HDL (mmol/L) 1.2 (0.13) 1.5 (0.16)
LDL (mmol/L) 0.6 (0.10) 0.6 (0.34)
ASAT (U/L) 63.5 (5.69) 87.0 (13.38)
ALAT (U/L) 38.7 (2.17) 83.6* (8.58)
ALP (U/L) 77.7 (4.03) 265.0* (23.54)
Urea (mmol/L) 6.9 (0.27) 11.2* (0.95)
Creatinine (mol/L) 26.2 (2.88) 25.6 (0.98)
Calcium (mmol/L) 2.8 (0.02) 3.2* (0.08)
Note: Data are mean ± (SE) of 6 samples/animals. The pa-
rameters show the serum glucose, in mmol/L, lipids (serum
cholesterol, triglyceride, HDL, LDL in mmol/L), liver enzymes
(serum ASAT, ALAT, ALP in U/L), kidney function (serum urea
in mmol/L, creatinine in mol/L) and the serum calcium level
in mmol/L). CHOL, total cholesterol; TG, triglyceride; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; ASAT,
aspartate aminotransferase; ALAT, alanine aminotransferase;
ALP, alkaline phosphatase. *p < 0.05 diabetic vs. nondiabetic
rats.
Table 3. Hematological laboratory parameters
of serum in diabetic and nondiabetic rats.
Nondiabetic
rats Diabetic rats
WBC (109/L) 4.0 (0.36) 2.8 (0.44)
RBC (1012/L) 8.1 (0.11) 7.4* (0.20)
HGB (g/L) 141.2 (2.24) 129.4* (2.80)
HCT (L/L) 0.4 (0.01) 0.4 (0.01)
MCV (fL) 47.3 (0.70) 50.8* (1.04)
MCH (pg) 17.5 (0.21) 17.6 (0.18)
MCHC (g/L) 369.3 (2.33) 346.8* (3.81)
PLT (109/L) 367.3 (10.92) 292.8* (22.53)
RDW-SD (%) 23.0 (0.54) 28.7* (1.24)
PDW (fL) 7.8 (0.28) 7.2 (0.22)
PCT (%) 0.3 (0.01) 0.2* (0.02)
Note: Data are mean ± (SE) of 6 samples/animals.
WBC, white blood cell (leukocytes); RBC, red blood
cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean
corpuscular volume; MCH, mean corpuscular hemo-
globin; MCHC, mean corpuscular hemoglobin con-
centration; PLT, platelet (thrombocyte); RDW-SD, red
blood cell distribution width standard deviation;
PDW, platelet distribution width; PCT, plateletcrit
(thrombocrit) reﬂects the mass of platelets. It is a
calculated value. Laser-based optical analyzers calcu-
lated plateletcrit as follows: Plateletcrit (%) = (MPV ×
PLT count) ÷ 1000. *p < 0.05 diabetic vs. nondiabetic
rats.
Table 4. Comparison of different inducers on diabetic and nondiabetic
rat platelet aggregation.
ADP
Arachidonic
acid Collagen
Nondiabetic rats
Area under the curve (U) 49.0 (4.2) 53.0 (4.6) 56.9 (3.1)
Maximal aggregation (AU) 75.5 (5.5) 80.2 (6.0) 78.3 (4.0)
Speed of aggregation (AU/min) 16.3 (1.8) 18.3 (2.0) 23.5* (1.3)
Diabetic rats
Area under the curve (U) 49.6 (4.6) 48.0 (4.6) 57.9 (3.6)
Maximal aggregation (AU) 73.5 (6.0) 70.1 (6.0) 78.2 (4.7)
Speed of aggregation (AU/min) 18.5 (2.0) 18.6 (2.0) 22.7 (1.6)
Note: Data are means ± (SE) of 6 samples/animals. U, unit; AU, arbitrary unit.
*p < 0.05 collagen vs. ADP.
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induced by the toxic effect of STZ. Toxic effects of STZ and diabetic
condition together lead to the development of dyslipidemia. The
detected portal congestion might be the consequence of liver fail-
ure caused by STZ. We presume that malabsorption caused by
portal congestion together with STZ-induced reduction of eryth-
ropoietin production by the kidney can induce anemic condition
and thrombocytopenia that we detected in the present experi-
ments.
It has already been published that the hyperreactivity of plate-
lets is an important complication during diabetes mellitus
(Ferreiro and Angiolillo 2011; Randriamboavonjy et al. 2012; Rofﬁ
et al. 2011). The hyperreactivity of thrombocytes may be also in-
duced indirectly. In this case the diabetic endothelial dysfunction
(releasing platelet activator factors and expressing adhesion re-
ceptors) can indirectly result in platelet activation (Paneni et al.
2013; Yeom et al. 2016). Hyperglycemia, hypoinsulinemia, dyslip-
idemia, and oxidative stress, during diabetic condition— alone or
in synergism — can directly activate the platelets (Ferreiro and
Angiolillo 2011). Hyperglycemia, by stimulating the receptor ex-
pression of platelets (Kotzailias et al. 2009), elevating the intracel-
lular calcium ion level (Liu et al. 2008), producing ROS (Tang et al.
2014), and activating the p38/MAP kinase pathway (Tang et al.
2011) leads to platelet adhesion, aggregation, and secretion. An
elevated serum glucose level also leads to the formation of ad-
vanced glycation end-products, and it can stimulate platelet
receptor expression and secretion (Gawlowski et al. 2009). More-
over, it has already been demonstrated that the low insulin level
also results in platelet activation (Ferreira et al. 2006).
Dyslipidemia (elevated LDL, decreased HDL) can stimulate
thromboxane synthesis due to the increased intracellular calcium
level (Pedreño et al. 2001; Siewiera et al. 2016). The apoptosis of
thrombocytes by oxidative stress has already been reported by
Leytin (2012). These processes, alone or together, might play a role
in the in vivo activation of circulating blood platelets, which may
Fig. 1. Effect of kisspeptin-13 (KP-13) on the collagen-induced aggregation of rat platelets. Data are mean ± SE of 6 samples/animals. U, unit;
AU, arbitrary unit. *p < 0.05 KP-13 vs. peptide-free sample.
Fig. 2. Effect of arginine phenylalanine (RF)-9 on the collagen-induced aggregation of rat platelets. Data are mean ± SE of 6 samples/animals.
U, unit; AU, arbitrary unit. *p < 0.05 RF-9 vs. peptide-free sample.
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explain the platelet number reduction in diabetic rats in the pres-
ent experiments. Yeom et al. (2016) also reported the elevated
adhesion of platelets and the reduction of platelet number in
diabetic rats in a time-dependent manner.
We detected that collagen was the most effective inducer for
the ex vivo examination of platelet aggregation, however we
could not ﬁnd signiﬁcant difference between the diabetic and
nondiabetic platelet aggregability. The application of this inducer
is supported by the fact that collagen plays an important role in
those pathological conditions in which endothelial dysfunction
participates. The similar ex vivo reaction of the diabetic and non-
diabetic platelets might be explained by the period of time elaps-
ing after the induction of diabetes. This is supported by the fact
that the effect of diabetes on platelet function (e.g., thromboxane
synthesis and adhesion) is also time-dependent (Siewiera et al.
2016; Yeom et al. 2016).
In addition to its several other effects, KP can prolong the bleed-
ing time and reduce the number of platelets in rats. This was
detected when KP-13 was applied intraperitoneally in vivo (Qureshi
and Kanwal 2011). In our earlier experiments we detected an en-
hancement of thromboxane (a potent vasoconstrictor and platelet
aggregator) synthesis of rat platelets in the presence of KP-13
(Mezei et al. 2015). In our present study, we observed that KP-13
enhanced the aggregation of nondiabetic platelets in a dose-
dependentmanner, in the presence of collagen as inducer. On the
other hand, this effect was only moderate in diabetic thrombo-
cytes. It has already been reported that KP (binding to the
G-protein coupled receptor and activating several intracellular
processes) can induce the elevation of intracellular calcium ion
(Kotani et al. 2001; Cvetkovic´ et al. 2013). We may suggest that the
KP-13-induced increase of nondiabetic platelet aggregation is
mediated by elevated intracellular calcium ion level, because it
participates in the activation of thromboxane synthesis, the
degranulation and the receptor expression of platelets. These
processes alone and together can support and accelerate the
aggregation process (Li et al. 2010).Wemay think that the reduced
ex vivo aggregability of diabetic platelets to KP-13 is explained by
the in vivo activation of diabetic platelets, which is demonstrated
by the degranulation of thrombocytes, the glycation of receptors,
and the alteration of membrane ﬂuidity (Randriamboavonjy et al.
2012). On the other hand, it has already been reported that the
glycation of cyclooxygenase enzyme (Angiolillo and Suryadevara
2009) and diabetic dyslipidemia (Watala et al. 2005; Kim et al.
2014) play a role in the development of aspirin resistance. Simonin
et al. (2006) reported that RF-9 binding to the NPFF-receptor, type 2
(NPFF2R) KP receptormight have a potentially antagonistic effect on
KP-13. In this case, RF-9 coupled to Gi/o protein should have re-
sulted in elevated cytoplasmic cyclic adenosine monophosphate
and reduced intracellular calcium ion level, and as a result, re-
duced platelet aggregation. In the present experiment, the appli-
cation of RF-9, even at a lower peptide concentration than KP-13,
induced hyperaggregability of nondiabetic platelets. We assume
that RF-9 is likely to have an effect not only on NPFF2 but also on
another receptor. This is also supported byMaletínská et al. (2013),
reporting that RF-9 is a partial agonist of KP receptor, and Min
et al. (2014), discussing RF-9 as a KP receptor agonist. In our exper-
iment using a pre-treatment with RF-9, we could not verify its
antagonistic effect on KP, moreover we demonstrated a synergy
with KP-13. Our results can be supported by the data published by
Kim et al. (2014), reporting that RF-9, the presumed antagonists of
NPFF1R, is in fact the agonist of both NPFF1R and the KP receptor
(KISS1R). The reason that the RF-9 pre-treatment induced even
stronger platelet activation (compared to the case when only KP
was used), can be found in that the elevation of the ic. Ca2+ level
induced by RF-9 may augment the expression of the platelet re-
ceptors (e.g., KISS1R) (Min et al. 2014; Babwah et al. 2012). Explor-
ing the mechanism of these diverging receptorial effects requires
further investigations.
In conclusion, it has been demonstrated that KP-13 was able to
enhance ex vivo collagen-induced aggregability of nondiabetic rat
platelets in a dose-dependentmanner, in which the enhancement
of thromboxane synthesis (as our team has already published)
may also play a role (Mezei et al. 2015). Streptozocin-induced ex-
perimental diabetes in rats did not induce signiﬁcant change in
the collagen-induced aggregability of platelets in vitro. This may
be explained by the long lasting in vivo activation of platelets
during the development of diabetes and their structural and func-
tional impairment. Under these experimental conditions RF-9 did
not prove to be an antagonist of KP-13, moreover it potentiated
platelet aggregation.
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Fig. 3. Effect of 5 × 10−8 mol/L kisspeptin-13 (KP-13) on the collagen-induced aggregation of arginine phenylalanine (RF)-9 pre-treated rat
platelets. Data are mean ± SE of 6 samples/animals. U, unit; AU, arbitrary unit. *p < 0.05 RF-9 vs. peptide-free sample.
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